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Spermidine is an endogenous polyamine whose increase induces the autocrine remodeling into 
targeted cells. The aim of the present study was to evaluate the adjunctive beneficial effects of the 
local delivery of spermidine to periodontal non-surgical therapy on reduction of periodontal pocket.
Methods
In this split mouth, blind, randomized controlled clinical trial, 20 patients with severe chronic 
generalized periodontal disease scheduled for cause related non-surgical periodontal treatment 
were enrolled. In three quadrants for each patients, three experimental teeth with probing pocket 
depth (PPD) ≥ 6mm were selected and randomly assigned to one of the following treatments: 
scaling and root planning (SRP)+ spermidine gel (spermidine + alginate) (group a), SRP+ placebo
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Abbreviations
Probing Pocket Depth (PPD); 
Full Mouth Plaque Scores (FMPS) 
Full Mouth Bleeding Scores (FMBS) 
Scaling and Root Planning (SRP)
Percentage of PPD reduction (%PPDr)
The treatment of periodontal disease consists in cause related therapy, the aim of which is to remove all local 
etiological factors and irritants such as plaque and calculus by powered or manual instruments, to obtain 
adequate compliance by the patient in the maintenance of a satisfying level of oral hygiene and to modify 
any modifiable negative habit. In most cases, such approach is effective at arresting the progression of the 
disease, bringing the periodontal tissue back to healthy conditions and eliminating periodontal pockets. 
However, cases in which infection is particularly aggressive and/or pockets defects are particularly deep or 
difficult to cleanse, further local or systemic therapeutic strategies are needed to reduce the bacteria load or 
to support the immune system [3]. Subsequently, any remaining periodontal pockets may be eliminated by 
a surgical approach that may contemplate the use of regenerative substances or biomaterials [4,5]. A large 
variety of drugs or substances that inhibit or eliminate periodontopathogenic microorganisms as well as 
modulate the inflammatory response of tissues has been proposed with the aim to make the cause-related 
therapy more effective, however so far only limited beneficial effects have been proved [3].
gel (only alginate) (positive control, group b) or SRP (negative control, group c). PPD at baseline, 3 
and 6 months after treatment was assessed. Descriptive and inferential statistics was done.
Results
After periodontal treatment, a reduction of PPD was observed in all sites. No differences emerged 
between groups at each time point. In all groups, a significant PPD reduction was observed at T1 
and T2 compared to baseline (p<0.05 and p<0.001). PPD reduction from T1 to T2 was significant 
only in group a (p<0.001).
Conclusions
After non-surgical treatment, local delivery of spermidine may induce prolonged improvement of 
clinical outcome.
Introduction
Periodontitis is a wide range of bacterially induced inflammatory diseases that cause the destruction of tooth 
supporting tissues (gingiva, periodontal ligament and bone) and the formation of periodontal pocket [1]. 
Extension and severity of periodontal tissue damage depends on different factors, such as the quality and 
quantity of bacteria, the host response and, for example, smoking or some systemic conditions [2]. The ratio 
between pro (bacteria, systemic diseases, risk factors..) and anti inflammatory (immune system) mechanisms 
will determine the story of the disease, that is usually slow and progressive [2].
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The aim of the present study was to assess if the local delivery of spermidine brings adjunctive beneficial 
effects to periodontal non-surgical therapy in terms of reduction of periodontal pocket.
Polyamines, namely putrescine, spermidine and spermine, are low molecular weight cationic molecules 
synthesized by many types of cells, especially those in tissues with high turnover, and also introduced with 
the common diet. Spermidine acts as conformation modifier on most biologically active, anionic biopolymers 
[6,7]. Such electrostatic, non-pharmacologic mode of action seems to end-up with the promotion of 
physiologic events including autophagy induction, immunomodulation, extracellular matrix turnover, 
cardioprotection, neuroprotection and stem cells activation [6,8]. Spermidine also has demonstrated in 
vitro to suppress the synthesis of pro-inflammatory cytokines [9-11] and to downregulate chemotaxis of 
polimorphonuclear leucocytes when administrated at concentrations similar to those found in gingival 
crevicular fluid [12]. Higher concentration of spermidine has also been found in tissues during inflammatory 
disease, suggesting a modulating activity mediated by the electrostatic interaction with the anionic mediators 
of the inflammatory patterns. The tissue content of spermidine was found to decrease with age and its 
higher levels in blood of nona/centenarians seemingly indicating a protective activity on tissue aging, thus 
improving human longevity [13].
This is a split mouth, blind, randomized controlled clinical trial. The study was approved by the ethical 
committee of Università degli Studi di Milano (n. 655, 3rd May 2016). All clinical procedures were performed 
in accordance with the ethical standards of the institutional and/or national research committee and with the 
1964 Helsinki declaration and its later amendments or comparable ethical standards for studies involving 
human participants.
20 patients with periodontal disease of Stage 3 Grade B scheduled for cause related non-surgical periodontal 
treatment were enrolled.
Participants
Due to its role as endogenous regulator, the delivery of spermidine on periodontal pockets may be proposed 
to improve/accelerate the periodontal tissue response and healing after non-surgical therapy of periodontitis. 
However the effect of this polyamine on periodontal status has not been assessed yet.
Study Population and Methodology
Study Design
The included patients presented the following inclusion criteria: age range: 25-80 years old; at least 3 
monoradicular teeth with probing pocket depth (PPD) ≥ 6mm distributed in three different quadrants; full 
mouth plaque (FMPS) and bleeding (FMBS) scores > 25% at the beginning of the study (baseline).
They all agreed to sign a written informed consent to take part to the study.
The following exclusion criteria were applied: current smokers or former smokers who had smoked in the 
previous 6 months; patients with clinically significant or unstable organic diseases, immune compromised
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subjects, subjects taking steroid medications or chronically treated (i.e., two weeks or more) with any 
medication known to affect periodontal status (i.e., antibiotics or NSAIDS), patients who took antibiotics 
within 90 days of baseline; patients displaying a compromised healing potential such as those affected 
by connective tissue disorders or bone metabolic diseases; patients with conditions requiring antibiotic 
prophylaxis; pregnant or lactating women, or women who were of childbearing potential and not using 
birth control or abstinence.
In each patient, three pockets with ≥ 6mm were assigned by a balanced random permuted block randomization 
approach to one of the following treatments: a) SRP + spermidine gel, b) SRP + placebo gel, c) SRP. In 
order to reduce the chance of unfavorable splits between treatment groups in terms of key prognostic factors, 
randomization process of the treatment assignment (a, b and c) of 3 experimental sites for each patient was 
done by the central registrar (DC) and took into account the mean PPD at baseline (PPD </> of 7mm). The 
treatment assignment was communicated to the operator (MT) immediately after scaling and root planning 
of all teeth.
At baseline, a full periodontal charting was completed for each enrolled patient. Intraoral radiographs of 
the experimental quadrants were also taken using A Rinn’s RING and a long cone parallel technique. In 
three quadrants for each patients, three experimental teeth with PPD ≥ 6mm were selected and assigned to 
one of the following treatments: scaling and root planning (SRP)+ spermidine gel (spermidine + alginate) 
(group a), SRP+ placebo gel (only alginate) (positive control, group b) or SRP (negative control, group c). 
After inclusion into the study, each patient was thereafter scheduled the next appointments for non-surgical 
periodontal treatments (T0), charting at 3 (T1) and 6 (T2) months of follow up. Briefly, all pockets were 
cleaned under local anesthesia by means of ultrasonic scalers and hand instrumentation (Gracey standard 
and mini five curettes), and the roots were planned. Non-surgical treatment was performed by the same 
operator (MT) following a quadrant by quadrant approach at Dental Building at San Paolo Hospital 
(Milan). Further mechanical instrumentation was not performed during the following 3 months.
Immediately after mechanical instrumentation, for each experimental pocket, one of the following treatments 
was performed: a) injection of gel with spermidine, b) injection of gel with placebo, c) no adjunctive treatment 
(Figure 1). Intraoral photographs of the experimental sites were taken before SRP, after 3 and 6 months.
Randomization
Treatment Procedures
Gaia Pellegrini, et al. (2019). Spermidine Associated to Non-Surgical Treatment of Periodontal Disease: 
Split Mouth Randomized Controlled Clinical Trial. CPQ Dentistry, 1(4), 01-12.
Gaia Pellegrini, et al., CPQ Dentistry (2019) 1:4 Page 5 of 12
Figure 1: Local delivery of spermidine gel into the periodontal pocket.
The following clinical measurements were taken at baseline, 3 (T1) and 6 (T2) months after SRP (T0) by 
a further blind operator (LC): FMPS and FMBS at four sites for all teeth; probing pocket depth (PPD) 
assessed at six sites of each tooth treated. All measurements were taken with a UNC periodontal probe (Hu 
Friedy Manufacturing Company Inc., Chicago, IL, USA).
The primary outcome of the study was PPD reduction. Sample size calculation was performed using α = 
0.05 (5%) and the power of sample 80%. For the variability the value of 0.8mm (ng/mL) (standard deviation 
of PPD) obtained in previous papers was considered [14]. The minimum significant value considered was 
1mm [14]. On the basis of these data, the needed number of patients to be enrolled resulted 17. Three more 
patients were enrolled considering a drop out of 15%.
Statistical Analysis
In each treatment group, mean and standard deviation were calculated for probing pocket depth (PPD) 
(mm) at baseline, 3 months after treatment, and 6 months after treatment. Furthermore the percentage of 
PPD reduction at T1 and T2 compared to baseline was computed.
To study the trend of PPD over time within each treatment group the Friedman test was applied for PPD. 
To compare data between treatment groups at each time point, data analysis was performed by means of 
Friedman test. In case of emerging significant differences, a paired t test was applied to calculate differences 
in PPD levels between the two groups for each time point. A paired t test was used to study differences 
between all time points in the same group. Furthermore a paired t test was used to assess differences on 
percentages of PPD reduction between treatment groups.
Clinical Measurements
Data were analyzed with SAS PROC MIXED (SAS Institute, Inc. 2008. SAS/STATVR 9.2 User’s guide. 
Cary, NC: SAS Institute, Inc). Level of significance was set for 5% (p < 0.05).
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A total of 20 patients (9 males and 11 females, mean age 54 years) non smokers and systemically healthy 
were enrolled in the present study. Patients were enrolled from July 2016 until March 2017 and follow-ups 
at 6 months were completed by September 2017.
After periodontal treatment, a reduction of PPD was observed in all sites. No significant differences emerged 
between groups at each time point, while significant differences resulted within each treatment group 
between time points (see table 1) (Friedman test). In all groups, a statistically significant PPD reduction 
was observed at T1 and T2 compared to baseline (p < 0.05 and p < 0.001). PPD reduction from T1 to T2 
resulted significant only in group a (p < 0.001).
Results
Study Population
At baseline, bleeding on probing was 33.55% (± 18.65) and significantly reduced at T1 (p < 0.05) and T2 
(p < 0.05) compared to baseline (paired t test, one tail). The plaque index was 48.52% (± 26.28) at baseline 
and significantly reduced at T1 (p < 0.05) and at T2 (p < 0.05) compared to baseline (paired t test, one tail).
Clinical Data
A total of 20 pockets for each group were treated and analyzed. Data on PPD for each group are reported 
in table 1. PPD at baseline was:
- in group a: 6mm in 12 sites, 7mm in 7 sites and 8mm in 1 site;
- in group b: 6mm in 14 sites, 7mm in 4 sites and 8mm in 2 sites;
- in group c: 6mm in 14 sites, 7mm in 5 sites and 8mm in 1 site.
Table 1: Data on periodontal pocket depth at each time point for groups. Significance of differences between time 
points (paired t test) and groups (Friedman test) has been indicated
Baseline T1 T2 T1 vs baseline (p) T2 vs baseline T2 vs T1
Group a 6.5 (±0.7) 4.4 (±0.69) 3.8 (±0.7) < .0005 < .0001 < .001
Group b 6.4 (±1.3) 4.5 (±0.9) 3.9 (±0.9) < .0001 < .0001 n.s.
Group c 6.4 (±1.1) 4.1 (±1.3) 4 (±0.9) < .0001 < .0001 n.s.
p between groups 
(Friedman test) n.s. n.s. n.s.
The mean percentage of PPD reduction (%PPDr) compared to baseline resulted 31.3% at T1 and 40.4% 
at T2 in group a, 29.9% at T1 and 38% at T2 in group b, 35.8% at T1 and 38.8% at T2 in group c. No 
significant differences were found between groups. The percentage of PPD reduction was also computed 
considering PPD at baseline 6mm or >6mm and is reported in table 2. No significant differences were found 
in %PPDr between sites with PPD 6mm at baseline and those with PPD > 6mm.
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Table 2: Mean percentage of periodontal pocket depth reduction for each group, separately indicated considering 
PPD at baseline 6mm or > 6mm
T1 vs baseline T2 vs baseline
PPD at baseline 6mm > 6mm 6mm > 6mm
Group a 27.8% 36.6% 33.3% 50.9%
Group b 26.2% 38.7% 35.7% 43.4%
Group c 33.3% 41.7% 35.7% 44.3%
Figure 2a: Pictures before treatment with placebo
Figure 2b: Pictures after treatment with placebo. Gingival tissue appears pink without edema. 
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In the present study the beneficial effects of spermidine locally delivered into periodontal pockets as 
adjunctive treatment to non-surgical therapy of periodontal disease were investigated. A split mouth 
randomized controlled study was drawn in order to eliminate interindividual differences concerning the 
response to the treatment at patient and operator level. From the analysis of data collected 3 months after 
treatment, it resulted that all the treatment options determined a significant improvement of clinical 
outcomes without differences between groups. However at the analysis of the reduction trend, only sites 
treated with spermidine demonstrated a prolonged (6 months) improvement of periodontal pocket depth 
compared to placebo and traditional non-surgical mechanical treatment. As reported above, polyamines and 
spermidine in particular, proven to play a non-pharmacologic, electrostatic micro-modification of some key 
protein involved in immune regulation [15]. Through this primary mode of action, spermidine exerts the 
synthesis inhibition of pro-inflammatory mediators including nitric oxide, prostaglandin E2 and cytokines 
such as tumor necrosis factor α and interleukin 1β [16]. In a rodent model of Parkinson disease it showed 
Figure 3a: Pictures before treatment with spermidine. The gingival inflammation due to plaque and calculus is 
evident
Figure 3b: Pictures after treatment with spermidine. The gingiva appears healed. The opening of the interdental 
spaces may indicate the resolution of the edema.
Discussion
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The local delivery of spermidine in addition to a non-surgical approach may improve the clinical outcomes 
of periodontal therapy by stimulating a prolonged repair capacity within periodontal cells. Further studies 
should be designed to investigate the effects of this polyamine on cells of periodontal tissues. It would be 
also interesting to assess the clinical effects of repeated deliveries of spermidine in periodontal pockets after 
non-surgical treatment in the long term.
antioxidant and anti-inflammatory properties [17]. Spermidine was also reported to favor the formation 
of CD8+ memory T cells via induction of autophagy [18]. CD8+ memory T cells were found to play a 
protective role on bone tissue, by promoting the secretion of anti-inflammatory cytokines (IL 10), the 
suppression of osteoclastogenesis, thus promoting bone regeneration [19]. Furthermore, CD8 T cells 
synthesize amphiregulin, a cytokine member of the epidermal growth factor family with anti-inflammatory 
properties [20]. This protein plays a crucial role in orchestrating the repair tissue activity of lungs, muscles and 
skin [21]. In periodontal tissue, inflammatory and reparative processes that follow non-surgical treatment 
may involve the activation of the immune system and induce the secretion of amphiregulin. Indeed, an 
in vitro study observed that epithelial cells rests of Malassez express amphiregulin [22]. In adults, such 
cells appear to play a role in maintaining the normal periodontal cellular elements and function and also 
seem an important source of stem cells that might play a pivotal role in periodontal regeneration [23]. 
In consideration of what is reported in literature, it could be supposed that the prolonged improvement 
of reduction of PPD that was found at 6 months in sites treated with spermidine leaded to a sustained 
tissue repair activity over time. To confirm this hypothesis, further studies assessing the immune response 
of periodontal tissue to spermidine should be designed. In the treatment of periodontal disease, the strategy 
of local delivery has been proposed with the aim to expose the infected/inflamed gingival tissue to high 
doses, under controlled release, of medications limiting the systemic involvement. Several drugs have been 
released in such way as an adjunct to scaling and root planning with the aim to reduce the pathogenetic 
biofilm, improve bone formation or contrast its resorption and reduce tissue inflammation. Bone stimulatory 
and anti inflammatory agents such as boric acid gel, simvastatin, rosuvastatin and atorvastatin have been 
clinically tested with encouraging results on the improvement of clinical parameters including pocket depth 
reduction and percentage of bone fill up to 6 months after delivery [24-26]. A recently published review 
observed that local antibiotics/antimicrobials can offer clinical improvements, in particular in persistent or 
recurrent localized deep sites, mostly when using vehicles with proven sustained release of the antimicrobial 
agent [27]. Local delivery of gels containing bisphosphonates were also investigated and resulted in a 
significant increase in PPD reduction and percentage of bone fill [14,28]. In the present study, non-surgical 
treatment was done following a quadrant-by-quadrant approach to limit contamination of control sites with 
spermidine during the initial healing phase. However this study design limited the blinding of the operator 
who performed the therapy [29].
Conclusion
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